Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the effect of the two new anticoagulants,
Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors. For
Dabigatran the investigators will test the non-specific inhibitors: prothrombin complex
concentrate (PCC), recombinant activated coagulation factor VII, and activated
prothrombin-complex (FEIBA). For Rivaroxaban the investigators will test a specific
Rivaroxaban decoy (FXa-GLAless). This will be done in a laboratory using blood plasma from
healthy male volunteers.